\"India is seeing a rise in digital transactions, and therefore industries are ramping up investments in Blockchain,\" says Ruchee Anand of LinkedIn

Diabetes drug price: Companies are talking of a significant price cut. Intas Pharmaceuticals, according to a senior official in the company, will hit the market today with two versions

Ogivri will be launched at a competitive discount for customers to help ensure increased access to treatment for thousands of HER2-positive breast and gastric cancer patients, said Biocon

Aurobindo Pharma share price gained 2.67% to Rs 462.2 compared to the previous close of Rs 450.20 on BSE

HDFC Bank shares will be in focus after the lender said it has constituted a six-member search committee to replace Aditya Puri as managing director and chief executive officer of the bank, whose tenure ends on October 26, 2020

Diagnostic imaging sector, largely dominated by big players, constitutes 36 per cent of the market, consumables and patient aids could be another 28 per cent, Invest India estimates

The new package rates finalised about a month ago are now up on the Ayushman Bharat website. Some private hospitals do not find the rates viable

Glenmark's current portfolio consists of 164 products authorised for distribution in the US marketplace and 44 abbreviated new drug applications pending approval with the USFDA

A number of biologics with huge markets are going off-patent in the US. Do Indian pharmaceutical companies have it in them to play this high-cost, high-risk game of launching biosimilars?

Rajiv Malik, President, Mylan, speaks about the impact the deal will have on India operations, the challenges in generic drugs and the role that China will play

Self-medication and indiscriminate use of drugs to treat acidity and gas will cause more harm than good. their prolonged use may have serious consequences

Snapping three-days losing streak, the share price of Unichem Laboratories opened higher, rising 7.4% to touch the day's high of Rs 164 apiece on the BSE

Cadila Healthcare share price has lost 29% in one year and fallen 27% since the beginning of this year

Prasad said there was a need for the government to focus on and invest more in primary healthcare

An improvement in exports to the US, the key market for Indian drug manufacturers, drove the growth in overall exports from India

The divestment will curtail 13 per cent global revenues of Lupin, which had posted Rs 16,369 crore consolidated revenues for the financial year ended March 31, 2019

Sun Pharma Q2 results: The drugmaker, which earns 37 per cent of its business from the US market, earned Rs 2,389.77 crore from the sale of formulations in the US in Q2FY20 against Rs 2397 crore in the corresponding quarter of the previous year

Sun Pharma Q2 results: India sales, which accounted for 31.6 per cent of total consolidated sales, rose 35 per cent year-on-year (YoY) to Rs 2,515 crore in September quarter of this fiscal

Lupin's net sales for the quarter stood at Rs 4,296 crore, an increase of 10.4 per cent compared to Rs 3,890 crore in the Q2FY19. The company posted a net loss of Rs 127 crore (after exceptional items) in Q2FY20, compared to Rs 266 crore net profit during the same quarter of the previous year

Cipla Q2 results: Consolidated revenue from India business grew 9 per cent yoy to Rs 1,810 crore, while international business delivered a growth of 8 per cent yoy at Rs 2,454 crore